Share Market Newspaper

(Albany, New York) – November 05, 2026: DelveInsight’s “Hemophilia A Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Hemophilia A market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hemophilia A Market Forecast

Some of the key facts of the Hemophilia A Market Report:

• The Hemophilia A market size across the 7MM was valued at approximately USD 12,918 million in 2025 and is anticipated to reach nearly USD 16,756 million by 2034, expanding at a CAGR of 2.9% across major markets, including the US, EU4, the UK, and Japan.

• In 2024, the United States accounted for the largest Hemophilia A market size among the 7MM, reaching nearly USD 5,920 million, with continued growth anticipated through 2034.

• In 2024, the Hemophilia A market size in Japan was estimated at approximately USD 1,150 million and is projected to witness growth throughout the forecast period from 2025 to 2034.

• In November 2026, Roche Expands Clinical Trial Sites for Phase III ZEBRHA 2 Study of NXT007: Roche expanded the number of participating clinical trial sites in its Phase III ZEBRHA 2 study evaluating NXT007 against emicizumab prophylaxis in patients with Hemophilia A, increasing the total from 59 to 63 locations. The study is designed to assess the efficacy and safety of NXT007 as a potential new prophylactic treatment option for individuals with Hemophilia A.

• In October 2026, Pfizer Expands Clinical Trial Sites for Phase III Marstacimab Program: Pfizer increased the number of participating clinical trial locations in its Phase III development program evaluating marstacimab in patients with Hemophilia A or B, both with and without inhibitors, from 75 to 78 sites. The ongoing study aims to further assess the long-term safety and efficacy of marstacimab as a prophylactic treatment for these patients.

• In October 2026, FDA Extends Review of Denecimig BLA: Novo Nordisk reported that the US FDA had extended its review of the Biologics License Application (BLA) for denecimig, being developed for adults and pediatric patients with Hemophilia A, both with and without inhibitors. The regulatory delay was related to ongoing remediation activities at the manufacturing facility in response to FDA feedback, rather than any concerns regarding the clinical efficacy or safety data. The company is working closely with the agency to fulfill the outstanding requirements, with a potential US launch anticipated in the first half of 2027, subject to regulatory approval.

• In September 2026, EMA’s CHMP Recommends Denecimig for Marketing Authorization: Novo Nordisk announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the approval of FREHEMGO (denecimig) for adults and pediatric patients with Hemophilia A, irrespective of inhibitor status. This investigational factor VIIIa-mimetic bispecific antibody is being developed as a subcutaneous prophylactic treatment with flexible dosing schedules of once weekly, once every two weeks, or once monthly. The recommendation was based on findings from the Phase III FRONTIER clinical development program.

• In July 2026, Novo Nordisk Announces Encouraging Phase III FRONTIER4 Results for Denecimig: Novo Nordisk reported interim findings from its Phase III FRONTIER4 extension study assessing investigational denecimig (Mim8) in patients aged one year and older with Hemophilia A, regardless of inhibitor status. The study enrolled 426 participants and demonstrated estimated mean annualized bleeding rates of 0.75 among adults and adolescents and 0.37 in children. Furthermore, approximately 71% of adults and adolescents and 89% of pediatric participants experienced no treated bleeding episodes across the evaluated dosing regimens.

• In June 2026, DA Expands Approval of HYMPAVZI (marstacimab): The US FDA approved an expanded indication for Pfizer’s HYMPAVZI (marstacimab-hncq) for routine prophylaxis in patients with Hemophilia A or B aged 12 years and older with inhibitors, as well as pediatric patients aged 6–11 years with or without inhibitors. The approval expands its use to younger patients with Hemophilia A and provides an additional once-weekly, subcutaneous prophylactic treatment option.

• In April 2026, The New England Journal of Medicine published 26-week findings from the Phase III FRONTIER2 trial assessing the efficacy and safety of once-monthly and once-weekly Denecimig in adults and adolescents aged 12 years and older with Hemophilia A, regardless of the presence of FVIII inhibitors. Investigational denecimig is a bispecific antibody that mimics activated Factor VIII (FVIIIa) and is designed as a routine prophylactic therapy to support blood clot formation. The therapy is currently being evaluated through the FRONTIER clinical program across multiple dosing schedules, patient age groups, and disease severities in individuals with hemophilia A, both with and without inhibitors.

• In March 2026, Belief BioMed (BBM) and Grand Life Sciences Group Co., Ltd. have announced an exclusive collaboration agreement. Under this partnership, Belief BioMed will grant Grand Life Sciences commercialization rights for its investigational therapy, BBM-H803, across Mainland China, Hong Kong, Macau, and Taiwan. The agreement reflects both companies’ commitment to combining their expertise and resources to accelerate the product’s commercialization, expand access to innovative treatments for hemophilia A patients, and support the advancement of the gene therapy sector. The agreement was formalized by Xiao Xiao, Co-founder, Chairman, and CSO of Belief BioMed, and Zenghui Feng, Chairman of Grand Life Sciences.

• In May 2025, the FDA approved Jivi (antihemophilic factor [recombinant], PEGylated-aucl; Bayer) for treating pediatric patients aged 7 and older with hemophilia A, as announced by Bayer.

• In May 2025, the FDA approved Antihemophilic factor (recombinant), PEGylated-aucl (Jivi; Bayer) for treating pediatric patients aged 7 and older with hemophilia A. The approval was supported by results from the Alfa-PROTECT and PROTECT Kids trials.

• In April 2025, the FDA approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce bleeding episodes in patients aged 12 and older with hemophilia A or B, with or without factor VIII or IX inhibitors.

• In March 2025, the US FDA approved QFITLIA (fitusiran) as the first antithrombin-lowering therapy indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (12 years and older) with hemophilia A or B, with or without factor VIII or IX inhibitors.

• In March 2025, Alnylam Pharmaceuticals announced the FDA’s approval of Qfitlia™ (fitusiran), the sixth Alnylam-discovered RNAi therapeutic approved in the U.S. It is the first and only treatment to lower antithrombin (AT), aiming to promote thrombin generation, rebalance hemostasis, and prevent bleeds.

• The epidemiology segment also provides the Hemophilia A epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

• The total diagnosed prevalent population of Hemophilia A in the 7MM comprised nearly 49,500 cases in 2024 and is projected to increase during the forecast period.

• The total diagnosed prevalent population of Hemophilia A in the United States was nearly 14,900 in 2024.

• EU4 and the UK contributed to the largest prevalent population of Hemophilia A, accounting for ~58% of the 7MM in 2024.

• In EU4 and the UK, the diagnosed prevalence of Hemophilia A was found to be maximum in France, followed by the UK. While the least number of cases were found in Spain in 2024.

• In 2024, the prevalent cases of mild Hemophilia A in the United States were identified to be ~35%, moderate as ~15%, and severe as ~50%.

• In the US, nearly 2,000 cases accounted for inhibitors and ~12,700 cases for non-inhibitors in 2024.

• Key Hemophilia A Companies: BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, CSL Behring, Novo Nordisk A/S, Bayer, Takeda, Sanofi, Biocad, Green Cross Corporation, Hoffmann-La Roche, Bayer, Spark Therapeutics, ASC Therapeutics, Hoffmann-La Roche, Shir, Carelon Research, and others

• Key Hemophilia A Therapies: rVIII-SingleChain, NNC0365-3769 (Mim8) PPX, Recombinant Factor VIII (Kovaltry, BAY81-8973), Adynovate, efanesoctocog alfa (BIVV001), ANB-010, GreenGene, NXT007, BAY2599023 (DTX201), SPK-8011, ASC618, Emicizumab, BAX 888, Rituximab, and others

• The Hemophilia A market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hemophilia A pipeline products will significantly revolutionize the Hemophilia A market dynamics.

Hemophilia A Overview

Hemophilia A is a genetic disorder that affects blood clotting. It is characterized by a deficiency or dysfunction of clotting factor VIII, which plays a crucial role in the blood coagulation process. Hemophilia A is the most common type of hemophilia, and it is also known as classic hemophilia.

Get a Free sample for the Hemophilia A Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/hemophilia-a2030-market

Hemophilia A Epidemiology

The Hemophilia A epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hemophilia A Epidemiology Segmentation:

The Hemophilia A market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM countries is segmented into:

• Total Prevalence of Hemophilia A

• Prevalent Cases of Hemophilia A by severity

• Gender-specific Prevalence of Hemophilia A

• Diagnosed Cases of Episodic and Chronic Hemophilia A

Download the report to understand which factors are driving Hemophilia A epidemiology trends @ Hemophilia A Epidemiology Forecast

Hemophilia A Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hemophilia A market or expected to get launched during the study period. The analysis covers Hemophilia A market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hemophilia A Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hemophilia A Therapies and Key Companies

• ROCTAVIAN (valoctocogene roxaparvovec): BioMarin Pharmaceutical

• Mim8: Novo Nordisk

• Peboctocogene camaparvovec (DTX201 or BAY2599023): Ultragenyx Pharmaceutical

• rVIII-SingleChain: CSL Behring

• NNC0365-3769 (Mim8) PPX: Novo Nordisk A/S

• Recombinant Factor VIII (Kovaltry, BAY81-8973): Bayer

• Adynovate: Takeda

• efanesoctocog alfa (BIVV001): Sanofi

• ANB-010: Biocad

• GreenGene: Green Cross Corporation

• NXT007: Hoffmann-La Roche

• BAY2599023 (DTX201): Bayer

• SPK-8011: Spark Therapeutics

• ASC618: ASC Therapeutics

• Emicizumab: Hoffmann-La Roche

• BAX 888: Shire

• Rituximab: Carelon Research

Discover more about therapies set to grab major Hemophilia A market share @ Hemophilia A Treatment Landscape

Hemophilia A Market Drivers

• Increasing Disease Awareness and Diagnosis: Growing awareness, improved diagnostic capabilities, and expanded screening programs are supporting the identification and treatment of Hemophilia A patients.

• Advancements in Novel Therapies: The development of non-factor replacement therapies, bispecific antibodies, and gene therapies is expanding treatment options and driving market growth.

• Rising Adoption of Prophylactic Treatments: Increasing preference for preventive treatment approaches to reduce bleeding episodes and joint damage is driving demand for effective prophylactic therapies.

• Growing Clinical Pipeline: Advancements in investigational therapies, including emicizumab alternatives, marstacimab, and denecimig, are creating new growth opportunities.

• Increasing Healthcare Investments: Greater investment in hematology research, clinical trials, and innovative treatment development is supporting the expansion of the Hemophilia A therapeutics market.

Hemophilia A Market Barriers

• High Treatment Costs: Expensive factor replacement therapies, gene therapies, and advanced biologics create significant financial burdens for patients and healthcare systems.

• Limited Treatment Accessibility: Unequal access to specialized healthcare facilities, diagnostic services, and advanced therapies, particularly in developing regions, restricts market penetration.

• Immunogenicity and Inhibitor Development: The development of factor VIII inhibitors in some patients can reduce treatment effectiveness and complicate disease management.

• Stringent Regulatory Requirements: Complex clinical development processes, long-term safety assessments, and regulatory uncertainties can delay the commercialization of novel therapies.

• Safety and Long-Term Efficacy Concerns: Potential adverse events, limited long-term clinical evidence, and uncertainties surrounding the durability of gene therapies may influence treatment adoption.

Scope of the Hemophilia A Market Report

• Study Period: 2020-2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Hemophilia A Companies: BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, =CSL Behring, Novo Nordisk A/S, Bayer, Takeda, Sanofi, Biocad, Green Cross Corporation, Hoffmann-La Roche, Bayer, Spark Therapeutics, ASC Therapeutics, Hoffmann-La Roche, Shir, Carelon Research, and others

• Key Hemophilia A Therapies: rVIII-SingleChain, NNC0365-3769 (Mim8) PPX, Recombinant Factor VIII (Kovaltry, BAY81-8973), Adynovate, efanesoctocog alfa (BIVV001), ANB-010, GreenGene, NXT007, BAY2599023 (DTX201), SPK-8011, ASC618, Emicizumab, BAX 888, Rituximab, and others

• Hemophilia A Therapeutic Assessment: Hemophilia A current marketed and Hemophilia A emerging therapies

• Hemophilia A Market Dynamics: Hemophilia A market drivers and Hemophilia A market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Hemophilia A Unmet Needs, KOL’s views, Analyst’s views, Hemophilia A Market Access and Reimbursement

To know more about Hemophilia A companies working in the treatment market, visit @ Hemophilia A Clinical Trials and Therapeutic Assessment

Table of Contents

1. Hemophilia A Market Report Introduction

2. Executive Summary for Hemophilia A

3. SWOT analysis of Hemophilia A

4. Hemophilia A Patient Share (%) Overview at a Glance

5. Hemophilia A Market Overview at a Glance

6. Hemophilia A Disease Background and Overview

7. Hemophilia A Epidemiology and Patient Population

8. Country-Specific Patient Population of Hemophilia A

9. Hemophilia A Current Treatment and Medical Practices

10. Hemophilia A Unmet Needs

11. Hemophilia A Emerging Therapies

12. Hemophilia A Market Outlook

13. Country-Wise Hemophilia A Market Analysis (2020-2034)

14. Hemophilia A Market Access and Reimbursement of Therapies

15. Hemophilia A Market Drivers

16. Hemophilia A Market Barriers

17. Hemophilia A Appendix

18. Hemophilia A Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services